Results 171 to 180 of about 880,593 (358)

Advances in the understanding of the Fanconi anemia tumor suppressor pathway [PDF]

, 2013
Anna Pickering, Jun Zhang, Jayabal Panneerselvam, Peiwen Fei   +3 more
openalex   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Regulatory counteraction to IL-2 activity. [PDF]

, 1983
Koszinowski, Ulrich H., Kramer, M.
core   +1 more source

Figure S1 from DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer

, 2023
Abigail L. Miller, Naiara Perurena, Alycia Gardner, Toshinori Hinoue, Patrick Loi, Peter W. Laird, Karen Cichowski   +6 more
openalex   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Commentary: LACTB is a tumour suppressor that modulates lipid metabolism and cell state [PDF]

, 2017
Ove Eriksson, Maciej Łałowski, Dan Lindholm   +2 more
openalex   +1 more source

Networks of tumor suppressors [PDF]

EMBO reports, 2000
M, Serrano, J, Massagué
openaire   +2 more sources

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

T cell functions by concanavalin A-induced suppressor T cell function test and autologous mixed lymphocyte reaction in various autoimmune diseases

, 1984
Masahide Takai, Kazuhiro Dohi, Yoshihiro Fujii, Hiroharu Yamada, Masao Kanauchi, Masakazu Hanatani, Hideo Nonaka, Hyoe Ishikawa   +7 more
openalex   +2 more sources

Mitotic Arrest by Tumor Suppressor RASSF1A Is Regulated via CHK1 Phosphorylation [PDF]

, 2013
Lingyan Jiang, Rong Rong, M. Saeed Sheikh, Ying Huang   +3 more
openalex   +1 more source